Cannabinoid CB1 receptors have been a potential target for nonopioid-based pain treatment, but actually targeting the pathway has been hindered by issues with tolerance and unwanted CNS side effects.

A receptor that cannabis latches onto in the brain could be a promising target for future mental health treatments.

The drug, known as VIP36, targets the body's cannabinoid receptor type 1 (CB1). It was found to be effective in three different animal models for pain and does not appear to cause the harmful side ...

Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development ...

Chemists designed the compound, known as VIP36, to bind cannabinoid receptor 1 (CB1) in the body but not in the brain. This design prevents the molecule from having psychoactive side effects.

Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid ...